Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 1
1995 2
1996 1
1997 1
1999 1
2004 1
2005 2
2006 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 2
2015 4
2016 1
2017 1
2019 4
2020 1
2021 2
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. Among authors: overmoyer ba. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. N Engl J Med. 2015. PMID: 25564897 Free PMC article. Clinical Trial.
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, Lang JE, Alpaugh M, Williams KP, Vaught D, Smith A, Smith K, Miller KD; Susan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation. Jagsi R, et al. Among authors: overmoyer ba. Breast Cancer Res Treat. 2022 Apr;192(2):235-243. doi: 10.1007/s10549-021-06434-x. Epub 2022 Jan 1. Breast Cancer Res Treat. 2022. PMID: 34973083 Free PMC article. Review.
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Stevens LE, Peluffo G, Qiu X, Temko D, Fassl A, Li Z, Trinh A, Seehawer M, Jovanović B, Alečković M, Wilde CM, Geck RC, Shu S, Kingston NL, Harper NW, Almendro V, Pyke AL, Egri SB, Papanastasiou M, Clement K, Zhou N, Walker S, Salas J, Park SY, Frank DA, Meissner A, Jaffe JD, Sicinski P, Toker A, Michor F, Long HW, Overmoyer BA, Polyak K. Stevens LE, et al. Among authors: overmoyer ba. Cancer Res. 2023 Jan 18;83(2):264-284. doi: 10.1158/0008-5472.CAN-22-0423. Cancer Res. 2023. PMID: 36409824 Free PMC article.
Inflammatory Breast Cancer: a Separate Entity.
Rosenbluth JM, Overmoyer BA. Rosenbluth JM, et al. Among authors: overmoyer ba. Curr Oncol Rep. 2019 Aug 15;21(10):86. doi: 10.1007/s11912-019-0842-y. Curr Oncol Rep. 2019. PMID: 31414257 Review.
Chemotherapy in the management of breast cancer.
Overmoyer BA. Overmoyer BA. Cleve Clin J Med. 1995 Jan-Feb;62(1):36-50. doi: 10.3949/ccjm.62.1.36. Cleve Clin J Med. 1995. PMID: 7859401 Free article. Review.
HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. Tarantino P, et al. Among authors: overmoyer ba. Eur J Cancer. 2022 Oct;174:277-286. doi: 10.1016/j.ejca.2022.07.001. Eur J Cancer. 2022. PMID: 36116830
31 results